Skip to main content
SpringerLink
Log in

Benzodiazepines in the Treatment of Alcoholism

  • Chapter
Recent Developments in Alcoholism

Part of the book series: Recent Developments in Alcoholism ((RDIA,volume 7))

Abstract

This chapter comprises three sections that cover the main aspects of benzodiazepines and alcohol: (1) the basic pharmacology of benzodiazepines; (2) use of benzodiazepines in the treatment of withdrawal; and (3) the use of benzodiazepines in treating alcoholics. The basic studies suggest that a major site of action of alcohol may be the GABA/benzodiazepine receptor complex and that compensatory alterations in this complex may underly withdrawal. In the section on alcohol withdrawal, interactions between the GABA/benzodiazepine receptor complex, sympathetic nervous system, and hypothalamic-pituitary-adrenal axis are discussed. Use of benzodiazepines in the treatment of the alcohol withdrawal syndrome are reviewed, including the possibility that the benzodiazepines may prevent withdrawal-induced “kindling.” Lastly, we review indications for, and efficacy of, benzodiazepines in long-term treatment of patients with alcoholism. Benzodiazepines are not indicated for the treatment of alcoholism. Furthermore, they have very few indications in alcoholics and their dependency-producing potency has to be appreciated when they are used in patients with alcoholism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Olivieri S, Cantopher T, Edwards JG: Two hundred years of dependence on anti-anxiety drugs. Human Psychopharmacol 1: 117–123, 1986.

    Google Scholar 

  2. Squires FR, Braestrup C: Benzodiazepine receptors in rat brain. Nature 266: 732–734, 1977.

    PubMed  CAS  Google Scholar 

  3. Mohler H, Okada R: Benzodiazepine receptor: Demonstration in the central nervous system. Science 98: 849–851, 1977.

    Google Scholar 

  4. Braestrup C, Nielsen M, Honore T, Jensen CH, Peterson EN: Benzodiazepine-GABA receptorionophore complex. Curr Cone Neuropharmacol 22: 1451–1458, 1983.

    CAS  Google Scholar 

  5. Chweh AY, Swinyard EA, Wold HH, Kupeferberg HJ: Correlations among minimal neurotoxicity, anticonvulsant activity, and displacing potencies in 3H-flunitrazepam binding of benzodiazepines. Epilepsia 24: 667–668, 1983.

    Google Scholar 

  6. Costa E, Guidotti A, Mao CC, Suria A: New concepts on the mechanism of action of benzodiazepines. Life Sci 17: 167–186, 1975.

    PubMed  CAS  Google Scholar 

  7. Choi DW, Farb DH, Fischbach GD: Chlordiazepoxide selectively augments GABA action on spinal cord cell cultures. Nature 269: 342–344, 1977.

    PubMed  CAS  Google Scholar 

  8. MacDonald R, Barker JL: Benzodiazepines specifically modulate GABA-mediated postsynaptic inhibition in cultured mammalian neurones. Nature 271: 563–564, 1978.

    PubMed  CAS  Google Scholar 

  9. Schoch P, Richards JG, Harving P, Takacs B, Stahli C, Staehelin T, Haefely W, Mohler H: Colocalisation of GABA-A receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature 314: 168-171.

    Google Scholar 

  10. Braestrup C, Squires RF: Brain specific benzodiazepine receptors. Br J Psychiatry 133: 249–260, 1978.

    PubMed  CAS  Google Scholar 

  11. Tallman JF, Thomas JW, Gallager DW: Gabaergic modulation of benzodiazepine binding site sensitivity. Nature 274: 383–385, 1978.

    PubMed  CAS  Google Scholar 

  12. Martin IL, Candy IM: Potentiation of benzodiazepine binding by sodium chloride and gammaaminobutyric acid. Neuropharmacology 17: 993–998, 1978.

    PubMed  CAS  Google Scholar 

  13. Costa E, Guidotti A, Toffano F: Molecular mechanisms mediating the action of diazepam on GABA receptors. Br J Psychiatry 133: 239–248, 1978.

    PubMed  CAS  Google Scholar 

  14. Skerritt JH, Willow M, Johnston GAR: Diazepam enhancement of low affinity GABA binding to rat brain membranes. Neurosci Lett 29: 63–66, 1982.

    PubMed  CAS  Google Scholar 

  15. Schofield PR, Darlison MG, Fujita N, Burt DR, Stephenson FA, Rodrigues H, Phee LM, Ramachandran J, Reale V, Glencorse TA, Seeburg PH, Barnard EA: Sequence and functional expressions of the GABA-A receptor shows a ligand-gated receptor super family. Nature 328: 221–227, 1987.

    PubMed  CAS  Google Scholar 

  16. Olsen RW: GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 37: 1–3, 1981.

    PubMed  CAS  Google Scholar 

  17. Ticku MK: Benzodiazepine-GABA receptor-ionophore complex: Current concept. Neuropharmacology 22: 128 1459–1470, 1983.

    PubMed  CAS  Google Scholar 

  18. Haefely WE: Tranquillizers, in Grahame-Smith DG, Hippius H, Winokur G (eds): Psychopharmacology I. Excerpta Medica, Amsterdam, pp 107–151.

    Google Scholar 

  19. Simmonds MA: Distinction between the effects of barbiturates benzodiazepines and phenytoin on responses to gamma-amino butyric acid receptor activation and antagonism by bicuculline and Picrotoxin. Br J Pharmacology 73: 739–747, 1981.

    CAS  Google Scholar 

  20. Study RE, Barker JL: Diazepam and (-)-pentobarbital: Fluctuation analysis reveals different mechanisms for potention of gamma-aminobutyric acid responses in cultured central neurones. Proc Natl Acad Sci USA 78: 7180–7184, 1981.

    PubMed  CAS  Google Scholar 

  21. Mathers DA: The GABA-A receptor: New insights from single channel recording. Synapse 1: 96–101, 1987.

    PubMed  CAS  Google Scholar 

  22. Cott JA, Carlsson A, Engel J, Lindqvist M: Supression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol 295: 203–209, 1976.

    PubMed  CAS  Google Scholar 

  23. Frye GD, Breese GR: GABAergic modulation of ethanol-induced motor impairment. J Pharm Exp Ther 223: 750–756, 1982.

    CAS  Google Scholar 

  24. Liljequist S, Engel J: Effects of GABAergic agonists and antagonists on various ethanol-induced behavioral changes. Psychopharmacology 78: 71–75, 1982.

    PubMed  CAS  Google Scholar 

  25. Martz A, Deitrich RA, Harris RA: Behavioral evidence for the involvement of gamma-aminobutyric acid in the actions of ethanol. Eur J Pharmacol 89: 53–62, 1983.

    PubMed  CAS  Google Scholar 

  26. Liljequist S, Engel JA: The effects of GABA and benzodiazepine receptor antagonists on the anti-conflict actions of diazepam or ethanol. Pharmacol Biochem Behav 21: 521–525, 1984.

    PubMed  CAS  Google Scholar 

  27. Banna NR: Potentiation of cutaneous inhibition by alcohol. Experientia 25: 619–620, 1969.

    PubMed  CAS  Google Scholar 

  28. Davidoff RS: Alcohol and presynaptic inhibition in isolated spinal cord preparation. Arch Neurol 28: 60–63, 1973.

    PubMed  CAS  Google Scholar 

  29. Nesteros JN: Ethanol specifically potentiates GABA-mediated neurotransmission in feline cerebral cortex. Science 209: 708–710, 1980.

    Google Scholar 

  30. Ticku MK: Behavioral and functional studies indicate a role for GABA-A-ergic transmission in the actions of ethanol. Alc Alcohol Suppl 1: 657–662, 1987.

    CAS  Google Scholar 

  31. Reggiani A, Barbaccia ML, Spano PF, Trabucchi M: Acute and chronic ethanol administration on specific 3H-GABA binding in different rat brain areas. Psychopharmacology 67: 261–264, 1980.

    PubMed  CAS  Google Scholar 

  32. Ticku MK, Burch TP, Davis WC: The interactions of ethanol with the benzodiazepine-GABA receptor-ionophore complex. Pharmacol Biochem Behav 18: 15–18, 1983.

    PubMed  CAS  Google Scholar 

  33. Seilicovich A, Duvilanski B, Gonzalez NN, Rettori V, DeNovara AM, Maines WM, DePlazas SF: The effect of acute ethanol administration on GABA receptor binding in cerebellum and hypothalamus. Eur J Pharmacol 111: 365–369, 1985.

    PubMed  CAS  Google Scholar 

  34. Suzdak PD, Schwartz RD, Skolnick P, Paul SM: Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. Proc Natl Acad Sci USA 83: 4071–4705, 1986.

    PubMed  CAS  Google Scholar 

  35. Ticku MK, Rastogi SK: Barbiturate-sensitive sites in the benzodiazepine-GABA receptor-ionophore complex, in Roth SH, Miller KW (eds): Molecular and Cellular Mechanisms of Anesthetics, New York, Plenum Press, 1986, pp 178–188.

    Google Scholar 

  36. Ticku MK, Lowrimore P, Lehoullier P: Ethanol enhances GABA-induced 36-CL-influx in primary spinal cord cultured neurons. Brain Res Bull 17: 123–126, 1986.

    PubMed  CAS  Google Scholar 

  37. Suzdak PD, Glowa JR, Crawley JN, Schwartz RD, Skolnick P, Paul SM: A selective imidazobenzodiazepine antagonist of ethanol in the rat. Science 234: 1243–1247, 1986.

    PubMed  CAS  Google Scholar 

  38. Liljequist S, Culp S, Tabakoff B: Ethanol-induced modulation of 35S-TBPS binding to brain membranes. Alc Alcohol 1: 653–656, 1987.

    CAS  Google Scholar 

  39. Mancillas JR, Siggins GR, Bloom FE: Systemic ethanol selective enhancement of responses to acetylcholine and somatostatin in hippocampus. Science 231: 161–163, 1986.

    PubMed  CAS  Google Scholar 

  40. Maksay G, Ticku MK: GABA, depressants and chloride ions affect the rate of dissociation of 35-S-t-butylbicydophosphorothionate binding. Life Sci 37: 2173–2180, 1985.

    PubMed  CAS  Google Scholar 

  41. Ticku MK, Davis WC: Evidence that ethanol and pentobarbital enhance 3H diazepam binding at the benzodiazepine-GABA receptor-ionophore complex indirectly. Eur J Pharmacol 71: 521–622, 1981.

    PubMed  CAS  Google Scholar 

  42. Rottenberg H: Alcohol modulation of benzodiazepine receptors. Alcohol 2: 203–207, 1985.

    PubMed  CAS  Google Scholar 

  43. Freund G: Benzodiazepine receptor loss in brains of mice after chronic alcohol consumption. Life Sci 27: 987–992, 1980.

    PubMed  CAS  Google Scholar 

  44. Rastogi SK, Thyagarajan R, Clothier J, Ticku MK: The effect of chronic treatment of ethanol on benzodiazepine and picrotoxin sites on the GABA-receptor complex in regions of the brain of the rat. Neuropharmacology 25: 1179–1184, 1986.

    PubMed  CAS  Google Scholar 

  45. Allan AM, Harris RA: Involvement of neuronal chloride channels in ethanol intoxication, tolerance and dependence, in Galanter M (ed): Recent Developments in Alcoholism, Vol. 5, 1987, pp 313–325.

    Google Scholar 

  46. Cowen PJ, Nutt DJ: Abstinence symptoms after withdrawal of tranquillizing drugs: Is there a common neurochemical mechanism? Lancet 2: 360–362, 1982.

    PubMed  CAS  Google Scholar 

  47. Salem N, Yoffe A, Kim Y, Karanian J, Taraschi T: Effects of fish oil and alcohol polyunsaturated lipids in membranes, in Lands WEM (ed): Polyunsaturated Fatty Acids and Eicosonoids. Champaign, Illinois, Am Oil Chemists Soc, 1987, pp 187–191.

    Google Scholar 

  48. Yoneda Y, Kuriyama K, Takahaski M: Modulation of synaptic GABA receptor binding by membrane phospholipids: Possible role of active oxygen radicals. Brain Res 333: 111–122, 1985.

    PubMed  CAS  Google Scholar 

  49. Braestrup C, Nielson M, Olsen C: Urinary and brain betacarboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc Natl Acad Sci USA 77: 2288–2292, 1980.

    PubMed  CAS  Google Scholar 

  50. Cowen P, Green A, Nutt D, Martin I: Ethyl-beta-carboline-carboxylate lowers seizures threshold and antagonizes flurazepam-induced sedation in rats. Nature 290: 54–55, 1981.

    PubMed  CAS  Google Scholar 

  51. File SE, Lister RG, Nutt DJ: The anxiogenic action of benzodiazepine antagonists. Neuropharmacology 21: 1033–1037, 1982.

    PubMed  CAS  Google Scholar 

  52. Dorrow R, Horowski R, Paschelke G, Amin M, Braestrup C: Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet 2: 98–99, 1983.

    Google Scholar 

  53. Nutt DJ: Pharmacological and behavioural studies on benzodiazepine antagonists and contragonists, in Biggio G, Costa E (eds): Benzodiazepine Recognition Site Ligands: Biochemistry and Pharmacology, New York, Raven Press, 1983, pp 153–173.

    Google Scholar 

  54. Nutt DJ, Cowen PC, Little HJ: Unusual interactions of benzodiazepine receptor antagonists. Nature 295: 436–438, 1982.

    PubMed  CAS  Google Scholar 

  55. Hunkeler W, Mohler H, Pieri L, Polc P, Bonetti EP, Cumin R, Schaffner R, Haefely W: Selective antagonists of benzodiazepines. Nature 290: 515–516, 1981.

    Google Scholar 

  56. Jensen CH, Petersen EN, Braestrup C, Honore T, Kehr W, Stephens DN, Schneider H, Seidelmann D, Schmiechen R: Evaluation of the beta-carboline ZK 93426 as a benzodiazepine antagonist. Psychopharmacology 83: 249–256, 1984.

    PubMed  CAS  Google Scholar 

  57. Haefely W: Tranquillizers, in Grahame-Smith DG, Cowen P (eds): Psychopharmacology II, New York, Elsevier, 1985, pp 92–182.

    Google Scholar 

  58. Barrett JE, Brady LC, Witkin JM: Behavioral studies with anxiolytic drugs. I. Interactions of the benzodiazepine antagonist Ro 15-1788 with chlordiazepoxide, pentobarbital and ethanol. J Pharmacol Exp Ther 233: 554–559, 1985.

    PubMed  CAS  Google Scholar 

  59. Hiltunen AJ, Jarbe TU: Discrimination of Ro 11-6896, chlordiazepoxide and ethanol in gerbils: Generalization and antagonism tests. Psychopharmacology 89: 284–290, 1986.

    PubMed  CAS  Google Scholar 

  60. Bonetti EP, Burkard WP, Gabl M, Mohler H: The partial inverse benzodiazepine agonist Ro 15-4513 antagonizes acute ethanol effects in mice and rats. Br J Pharmacol 86: 463, 1985.

    Google Scholar 

  61. Polc P: Interactions of partial inverse benzodiazepines agonist Ro 15-4513 and FG 7142 with ethanol in rats and cats. Br J Pharmacol 86: 465, 1985.

    Google Scholar 

  62. Bonetti EP, Polc P, Pieri L: An azido analogue of the benzodiazepine antagonist Ro 15-1788 (Ro 15-4513) behaves as a partial inverse benzodiazepine agonist. Neurosci Lett Suppl 18: 530, 1984.

    Google Scholar 

  63. Mereu G, Passino N, Carcangiu P, Boi V, Gessa GL: Electrophysiological evidence that Ro 15-4513 is a benzodiazepine receptor inverse agonist. Eur J Pharmacol 135: 453–454, 1987.

    PubMed  CAS  Google Scholar 

  64. Miczek KA, Weerts EM: Seizures in drug treated animals. Science 235: 1127, 1987.

    PubMed  CAS  Google Scholar 

  65. Nutt DJ, Lister RG: The effect of the imidazodiazepine Ro 15-4513 on the anticonvulsant effects of diazepam, sodium pentobarbital and ethanol. Brain Res 413: 193–196, 1987.

    PubMed  CAS  Google Scholar 

  66. Lister RG, Nutt DJ: Interactions of the imidazodiazepine Ro 15-4513 with chemical convulsants. Br J Pharmacol 93: 210–214, 1987.

    Google Scholar 

  67. Harris CM, Benjamin D, Lal H: Anxiety-like subjective effects of ethanol antagonist Ro 15-4513 demonstrated in pentylene-tetrazol discrimination. Neuropharmacology, 26: 1545-1547.

    Google Scholar 

  68. Lister RG: Interactions of Ro 15-4513 with diazepam, sodium pentobarbital and ethanol in a holeboard test. Pharmacol Biochem Behav 28: 75–79, 1987.

    PubMed  CAS  Google Scholar 

  69. Britton KT, Ehlers CL, Koob GF: Ethanol antagonist Ro 15-4513 is not selective for ethanol. Science 1239: 648–649, 1988.

    Google Scholar 

  70. Hoffman PL, Tabakoff B, Szabo G, Suzdak PD, Paul SM: Effect of an imidazobenzodiazepine, Ro 15-4513, on the incoordination and hypothermia produced by ethanol and pentobarbital. Life Sci 41: 611–619, 1987.

    PubMed  CAS  Google Scholar 

  71. Koob GF, Braestrup C, Britton KT: The effects of FG 7142 and Ro 15-1788 on the release of punished responding produced by chlordiazepoxide and ethanol in the rat. Psychopharmacology 90: 173–178, 1986.

    PubMed  CAS  Google Scholar 

  72. Lister RG, Nutt DJ: Is Ro 15-4513 a specific alcohol antagonist? Trends Neurosci 10: 223–225, 1987.

    CAS  Google Scholar 

  73. Lister RG, Karanian JN: Ro 15-4513 Induces seizures in DBAJ2 mice undergoing alcohol withdrawal. Alcohol 4: 409–411, 1987.

    PubMed  CAS  Google Scholar 

  74. Rommelspacher H: The B-carbolines—a new class of endogenous compounds: Their relevance for the pathogenesis and treatment of psychiatric and neurological diseases. Pharmacopsychiatria 14: 117–125, 1981.

    PubMed  CAS  Google Scholar 

  75. Differential effects on benzodiazepine disposition by disulfiram and ethanol. Arzneim Forschung 30: 882-886, 1980.

    Google Scholar 

  76. Bhattacharya SK, Glover V, Sandier M, Clow A, Topham A, Bernadt M, Murray R: Raised endogenous monoamine oxidase inhibitor output in postwithdrawal alcoholics: Effects of L-dopa and ethanol. Biol Psychiatry 17: 687–694, 1982.

    Google Scholar 

  77. Petursson H, Reveley MA, Glover V, Sandler M: Urinary MAO inhibitor in psychiatric illness. Psychiatry Res 5: 335–340, 1981.

    PubMed  CAS  Google Scholar 

  78. Little JH, Taylor SC, Nutt DJ: The benzodiazepine antagonist Ro 15-1788 does not decrease ethanol withdrawal convulsions in rats. Eur J Pharmacol 107: 375–377, 1985.

    PubMed  CAS  Google Scholar 

  79. Adinoff B, Majchrowicz E, Martin PR, Linnoila M: The benzodiazepine antagonist Ro 15-1788 does not antagonize the ethanol withdrawal syndrome. Biol Psychiatry 21: 643–649, 1986.

    PubMed  CAS  Google Scholar 

  80. Majewska MD, Harrison NC, Schwartz RD, Barker JC, Paul SM: Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232: 1004–1007, 1986.

    PubMed  CAS  Google Scholar 

  81. Harrison NC, Majewska MD, Harrington JW, Barker JL: Structure—activity relationships for steroid interaction with the gamma-aminobutyric acid A receptor complex. J Pharmacol Exp Ther 241: 346–353, 1987.

    PubMed  CAS  Google Scholar 

  82. Alho H, Costa E, Ferrero P, Fujimoto M, Cosenza-Murphy D, Guidotti A: Diazepam binding inhibitor: A neuropeptide located in selected neuronal populations of rat brain. Science 229: 179–182, 1985.

    PubMed  CAS  Google Scholar 

  83. Barbaccia ML, Costa E, Ferrero P, Guidotti A, Roy A, Sunderland T, Pickar D, Paul SM, Goodwin FK: Diazepam binding inhibitor. Arch Gen Psychiatry 43: 1143–11147, 1986.

    PubMed  CAS  Google Scholar 

  84. Ferrero P, Guidotti A, Conti-Tronconi B, Costa E: A brain octadecaneuropeptide generated by tryptic digestion of DBI functions as a proconflict ligand of benzodiazepine recognition sites. Neuropharmacology 23: 1359–1362, 1984.

    PubMed  CAS  Google Scholar 

  85. Frye GD, McCown TJ, Breese GR, Peterson SL: GABAergic modulation of inferior colliculus excitability: Role in the ethanol withdrawal audiogenic seizures. J Pharmacol Exp Ther 237: 478–485, 1986.

    PubMed  CAS  Google Scholar 

  86. deVries DJ, Ward LC, Wilce PA, Johnston GAR, Shanley BC: Effect of ethanol on the GABA-benzodiazepine receptor in brain. Alc Alcohol Suppl 22: 663–667, 1987.

    Google Scholar 

  87. Lescaudron L, Seguela P, Geffard M, Verna A: Effects of long term ethanol consumption on GABAergic neurons in the mouse hippocampus: A quantitative immunocytochemical study. Drug Alc Depend 18: 377–386, 1986.

    CAS  Google Scholar 

  88. Volicer L, Biagioni TM: Effect of ethanol administration and withdrawal on benzodiazepine receptor binding in the rat brain. Neuropharmacology 21: 283–286, 1981.

    Google Scholar 

  89. Liljequist S, Tabakoff B: Binding characteristics of 3H flunitrazepam and CL-218, 872 in cerebellum and cortex of C57B1 mice made tolerant to, and dependent on, phenobarbital and ethanol. Alcohol 2: 215–220, 1985.

    PubMed  CAS  Google Scholar 

  90. Gallager DW, Lakoski JM, Gonsalves SF, Rauch SL: Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature 308: 74–77, 1984.

    PubMed  CAS  Google Scholar 

  91. Gallaher EJ, Hollister LE, Gionet SE, Crabbe JC: Mouse lines selected for genetic differences in diazepam sensitivity. Psychopharmacology 93: 25–30, 1987.

    PubMed  CAS  Google Scholar 

  92. Hellevuo K, Kiianmaa K, Juhakoski A, Kim C: Intoxicating effects of lorazepam and barbital in rat lines selected for differential sensitivity to ethanol. Psychopharmacology 91: 263–267, 1987.

    PubMed  CAS  Google Scholar 

  93. Marley RJ, Wehner JM: GABA enhancement of flunitrazapem binding in mice selectively bred for differential sensitivity to ethanol. Alc Drug Res 7: 25–32, 1987.

    CAS  Google Scholar 

  94. Crabbe JC, Young ER, Tarn B, Kosobud A, Belknap JK, Laursen SE: Genetic differences in anticonvulsant sensitivity in mouse lives selectively bred for ethanol withdrawal sensitivity. J Pharmacol Exp Ther 239: 154–159, 1986.

    PubMed  CAS  Google Scholar 

  95. Nutt DJ, Lister RG: Strain differences in response to a benzodiazepine receptor inverse agonist (FG 7142) in mice. Psychopharmacology, 94: 435–436, 1988.

    Google Scholar 

  96. Wang JKT, Taniguchi T, Spector S: Properties of 3H-diazepam binding sites on rat blood platelets. Life Sci 27: 1881–1888, 1980.

    PubMed  CAS  Google Scholar 

  97. Schoemaker H, Bliss M, Yamamura HI: Specific high-affinity saturable binding of 3H-Ro 5-4864 to benzodiazepine binding sites in the rat cerebral cortex. Eur J Pharmacol 71: 173–175, 1981.

    PubMed  CAS  Google Scholar 

  98. Tamborska E, Marangos PJ: Brain benzodiazepine binding sites in ethanol dependent and withdrawal states. Life Sci 38: 465–472, 1987.

    Google Scholar 

  99. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC, 1980.

    Google Scholar 

  100. Jaffe JH, Domenic AC, Nies A, Dixon RB, Monroe LL: Abuse potential of halazepam and of diazepam in patients recently treated for acute alcohol withdrawal. Clin Pharmacol Ther 34: 623–630, 1983.

    PubMed  CAS  Google Scholar 

  101. Linnoila M, Martin PR: Benzodiazepines and alcoholism, in Trimble R (ed): Benzodiazepines Divided. New York, John Wiley and Sons, 1983, pp 291–308.

    Google Scholar 

  102. Sellers EM, Kalant H: Alcohol withdrawal and delerium tremens, in Pattison EM, Kaufman E (eds): The Encyclopedic Handbook of Alcoholism. New York, Gardner Press, 1983, pp 147–166.

    Google Scholar 

  103. Meldrum B; Anticonvulsant drugs and GABA-mediated inhibition, in Sandier M (ed): Psychopharmacology of Anticonvulsants, Oxford, Oxford University Press, 1982, pp 62–78.

    Google Scholar 

  104. Sjoquist B, Borg S, Kvande H: Catecholamine derived compounds in urine and cerebrospinal fluid from alcoholics during and after long-standing intoxication. Subst Al Actions Misuse 2: 63–72, 1981.

    CAS  Google Scholar 

  105. Borg S, Kvande H, Sedvall G: Central norepinephrine metabolism during alcohol intoxication in addicts and healthy volunteers. Science 213: 1135–1137, 1981.

    PubMed  CAS  Google Scholar 

  106. Hawley RJ, Major LF, Schulman EA, Linnoila M: Cerebrospinal fluid 3-methoxy-4-hydroxy-phenyglycol and norepinephrine levels in alcohol withdrawal. Arch Gen Psychiatry 42: 1056–1062, 1985.

    PubMed  CAS  Google Scholar 

  107. Borg S, Czarnecka A, Kvande H, Mossberg D, Sedvall G: Clinical conditions and concentrations of MOPEG in the cerebrospinal fluid and urine of male alcoholic patients during withdrawal. Alcoholism 7: 411–415, 1983.

    PubMed  CAS  Google Scholar 

  108. Bjorkqvist SE: Clonidine in alcohol withdrawal. Acta Psychiat Scand 52: 256–263, 1975.

    PubMed  CAS  Google Scholar 

  109. Wilkins AJ, Jenkins WJ, Steiner JA: Efficacy of Clonidine in treatment of alcohol withdrawal state. Psychopharmacology 81: 28–38, 1983.

    Google Scholar 

  110. Glue P, Nutt D: Clonidine in alcohol withdrawal: A pilot study of differential symptom responses following I.V. Clonidine, Alc Alcohol 22: 161–166, 1987.

    CAS  Google Scholar 

  111. Yoshishige I, Masatoshi T, Tsuda A, Tsujimaru S, Nagasaki N: Attenuating effect of diazepam on stress induced in noradrenaline turnover in specific brain regions of rats: Antagonism by Ro 15-1788. Life Sci 37: 2491–2498, 1985.

    Google Scholar 

  112. Taylor KM, Laverty R: The effect of chlordiazepoxide, diazepam and nitrazepam on catecholamine metabolism in regions of the rat brain. Eur J Pharmacol 8: 296–301, 1969.

    PubMed  CAS  Google Scholar 

  113. Corrodi H, Fuxe K, Lidbrink P, Olson L: Minor tranquillizers, stress and central catecholamine neurons. Brain Res 29: 1–16, 1971.

    PubMed  CAS  Google Scholar 

  114. Grant SJ, Huang YH, Redmond DE Jr: Benzodiazepines attenuate single unit activity in the locus coeruleus. Life Sci 27: 2231–2236, 1980.

    PubMed  CAS  Google Scholar 

  115. Charney DS, Heninger GR, Redmond DE Jr: Yohimbine induced anxiety and increased noradrenergic function in humans: Effects of diazepam and Clonidine. Life Sci 33: 19–29, 1983.

    PubMed  CAS  Google Scholar 

  116. Tabakoff B, Jaffe RC, Ritzmann RF: Corticosterone concentration in mice during ethanol drinking and withdrawal. J Pharm Pharmacol 30: 371–374, 1978.

    PubMed  CAS  Google Scholar 

  117. Rivier C, Bruhm T, Vale W: Effects of ethanol on the hypothalamic-pituitary-adrenal axis in the rat: Role of corticotropin-releasing factor (CRF). J Pharmacol Exp Ther 229: 127–131, 1985.

    Google Scholar 

  118. Pohorecky LA, Newman B, Sun J, Bailey WH: Acute and chronic ethanol ingestion and serotonin metabolism in rat brain. J Pharmacol Exp Ther 204: 424–432, 1978.

    PubMed  CAS  Google Scholar 

  119. Risher-Flowers D, Adinoff B, Ravitz B, Bone GHA, Nutt D, Martin PR, Linnoila M: Orcadian rhythms of cortisol during alcohol withdrawal. Adv Alc Subst Abuse, in press.

    Google Scholar 

  120. Merry J, Marks V: The effect of alcohol, barbiturate, and diazepam on hypothalamic/pituitary adrenal function in chronic alcoholics. Lancet October: 2: 990–992, 1972.

    PubMed  CAS  Google Scholar 

  121. Mendelson WB, Martin JV, Wagner R, Roseberry C, Skolnik P, Weissman BA, Squires R: Are the toxicities of pentobarbital and ethanol mediated by the GABA-benzodiazepine receptor-chloride ionophore complex? Eur J Pharmacol 108: 63–70, 1985.

    PubMed  CAS  Google Scholar 

  122. Valimaki M, Pelkonen R, Harkonen M, Ylikahri: Harmonal changes in noncirrhotic male alcoholics during ethanol withdrawal. Alc Alcohol 19: 235–242, 1984.

    CAS  Google Scholar 

  123. Sapolsky RM, Pulsinelli WA: Glucocorticoids potentiate ischemic injury to neurons: Therapeutic implications. Science 236: 1397–1400, 1985.

    Google Scholar 

  124. de Kloet ER: Adrenal steroids as modulators of nerve cell function. J Steroid Biochem 20: 175–181, 1984.

    PubMed  Google Scholar 

  125. Henkin RI: The effects of corticosteroids and ACTH on sensory systems. Prog Brain Res 32: 270–293, 1970.

    PubMed  CAS  Google Scholar 

  126. Haskett RF: Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry 142: 911–921, 1985.

    PubMed  CAS  Google Scholar 

  127. Starkman MN, Schteingart DE, Schork MA: Cushing’s syndrome after treatment: Changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 19: 177–188, 1986.

    PubMed  CAS  Google Scholar 

  128. Ling MHM, Perry PJ, Tsuang MT: Side effects of corticosteroid therapy. Arch Gen Psychiatry 38: 471–477, 1981.

    PubMed  CAS  Google Scholar 

  129. Rubinov DR, Post RM, Savard R, Gold PW: Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiatry 41: 279–283, 1984.

    Google Scholar 

  130. Sze PY, Yanai J, Ginsburg BE: Adrenal glucocorticoids as a required factor in the development of ethanol withdrawal seizures in mice. Brain Res 80: 155–159, 1974.

    PubMed  CAS  Google Scholar 

  131. Targum SD, Wheadon DE, Chastek CT, McCabe WJ, Advani MT: Dysregulation of hypothalamic-pituitary-adrenal axis function in depressed alcoholic patients. J Affect Disord 4: 347–353, 1982.

    PubMed  CAS  Google Scholar 

  132. Crawley JN, Ninan PT, Pickar D, Chrousos GP, Linnoila M, Skolnick P, Paul SM: Neuropharmacological antagonism of the β-carboline-induced “anxiety” response in rhesus monkeys. J Neurosci 5: 477–485, 1985.

    PubMed  CAS  Google Scholar 

  133. Kalin NH, Shelton SE, Barksdale CM: Separation distress in infant rhesus monkeys: Effects of diazepam and Ro 15-1788. Brain Res 408: 192–198, 1987.

    PubMed  CAS  Google Scholar 

  134. Mormede P, Dantzer R, Perio A: Relationship of the effects of the benzodiazepine derivative clorazepate on corticosterone secretion with its behavioural actions: Antagonism by Ro 15-1788. Pharmacol Biochem Behav 21: 839–843, 1984.

    PubMed  CAS  Google Scholar 

  135. Bizzi A, Ricci MR, Veneroni E, Amato M, Garattini S: Benzodiazepine receptor antagonists reverse the effect of diazepam on plasma corticosterone in stressed rats. J Pharm Pharmacol 36: 134–135, 1984.

    PubMed  CAS  Google Scholar 

  136. Sellers EM, Kalant H: Alcohol intoxication and withdrawal. N Engl J Med 294: 757–762, 1976.

    PubMed  Google Scholar 

  137. Shaw JM, Kolesar GS, Sellers EM, Kaplan HL, Sandor P: Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1: 382–389, 1981.

    PubMed  CAS  Google Scholar 

  138. Whitfield CL, Thompson G, Lamb A, Spencer V, Pfeifer M, Browning-Ferrando M: Detoxification of 1024 alcoholic patients without psychoactive drugs. J Am Med Assoc 239: 1409–1410, 1978.

    CAS  Google Scholar 

  139. Knott DH, Lerner WD, Davis-Knott T, Fink RD: Decision for alcohol detoxication. Postgrad Med 69: 65–78, 1981.

    PubMed  CAS  Google Scholar 

  140. Olbrich R: Alcohol withdrawal states and the need for treatment. Br J Psychiatry 134: 466–469, 1979.

    PubMed  CAS  Google Scholar 

  141. Holloway HC, Hales RE, Watanabe HK: Recognition and treatment of acute alcohol withdrawal syndromes. Psychiatr Clinic NA 4: 729–743, 1984.

    Google Scholar 

  142. Elton M: Alcohol withdrawal: Clinical symptoms and management of the syndrome. Acta Psychiatr Scand 327: 80–90, 1986.

    CAS  Google Scholar 

  143. Kaim SC, Klett CJ, Rothfield B: Treatment of the acute alcohol withdrawal state: A comparison of four drugs. Am J Psychiatry 125: 1640–1646, 1969.

    PubMed  CAS  Google Scholar 

  144. Thompson WL, Johnson AD, Maddrey WL, Osler Medical Housestaff: Diazepam and paraldehyde for treatment of severe delirium tremens. Ann Intern Med 82: 175–180, 1975.

    PubMed  CAS  Google Scholar 

  145. Moskowitz G, Chalmers TC, Sacks HS, Fagerstrom RM, Smith H: Deficiencies of clinical trials of alcohol withdrawal. Alcohol Clin Exp Res 7: 42–46, 1983.

    PubMed  CAS  Google Scholar 

  146. Devenyi P, Harrison ML: Prevention of alcohol withdrawal seizures with oral diazepam loading. Can Med Assoc J 132: 798–800, 1985.

    PubMed  CAS  Google Scholar 

  147. Potter JF, Bannan LT, Beevers DG: The effects of a nonselective lipophilic beta-blocker on the blood pressure and noradrenaline, Vasopressin, Cortisol, and renin release during alcohol withdrawal. Clin Exp Hypertension A6: 1147–1160, 1984.

    Google Scholar 

  148. Kraus ML, Gottlieb LD, Horwitz RI, Auscher M: Randomized trial of atenolol in patients with alcohol withdrawal. N Engl J Med 313: 905–909, 1983.

    Google Scholar 

  149. Burroughs AK, Morgan MY, Sherlock S: Double-blind controlled trial of bromocriptine, chlordiazepoxide, and chlormethiazole for alcohol withdrawal symptoms. Alc Alcohol 20: 263–271, 1985.

    CAS  Google Scholar 

  150. Motto JA: Acute alcohol-withdrawal syndromes: A controlled study of phenothiazine effectiveness. Q J Stud Alcohol 29: 917–930, 1968.

    PubMed  CAS  Google Scholar 

  151. Palestine ML, Alatorre E: Control of acute alcoholic withdrawal symptoms: A comparative study of haloperidol and chlordiazepoxide. Curr Therapeut Res 20: 289–299, 1976.

    CAS  Google Scholar 

  152. Wilson A, Vulcano B: A double-blind, placebo-controlled trial of magnesium sulfate in the ethanol withdrawal syndrome. Alcohol Clin Exp Res 8: 542–549, 1984.

    PubMed  CAS  Google Scholar 

  153. Hansbrough JF, Zapata-Sirvnet RL, Carroll WJ, Johnson R, Saunders CE, Barton CA: Administration of intravenous alcohol for prevention of withdrawal in alcoholic burn patients. Am J Surg 148: 266–269, 1984.

    PubMed  CAS  Google Scholar 

  154. Gower WE, Kersten H: Prevention of alcohol withdrawal symptoms in surgical patients. Surg, Gyn Obst 151: 382–384, 1980.

    CAS  Google Scholar 

  155. Pentikainen PJ, Valtonen VV, Miettinin TA: Deaths in connection with chlormethiazole (Heminevrin) therapy. Int J Clin Pharmacol 14: 225–230, 1976.

    CAS  Google Scholar 

  156. Horder JM: Fatal chlormethiazole poisoning in chronic alcoholics. Br Med J 1: 693–694, 1978.

    PubMed  CAS  Google Scholar 

  157. Jacob MS, Zilm DH, Macleod SM, Sellers EM: Propranolol-associated confused states during alcohol withdrawal. J Clin Psychopharmacol 3: 185–187, 1983.

    PubMed  CAS  Google Scholar 

  158. Wilbur R, Kulik FA: Anticonvulsant drugs in alcohol withdrawal: Use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants. Am J Hosp Pharm 38: 1138–1143, 1981.

    PubMed  CAS  Google Scholar 

  159. Butler D, Messiha FS: Alcohol withdrawal and carbamazepine. Alcohol 3: 113–129, 1986.

    PubMed  Google Scholar 

  160. Walinder J, Balldin J, Bokstrom K, Karlsson I, Lundstrom B: Clonidine suppression of the alcohol withdrawal syndrome. Drug Alc Depend 8: 345–348, 1981.

    CAS  Google Scholar 

  161. Baumgartner GR, Rowen RC: Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch Intern Med 147: 1223–1226, 1987.

    PubMed  CAS  Google Scholar 

  162. Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K: Diazepam loading: Simplified treatment of alcohol withdrawal. Clin Pharmacol Ther 34: 822–926, 1983.

    PubMed  CAS  Google Scholar 

  163. Korttila K, Linnoila M: Absorption and sedative effects of diazepam after oral administration and intramuscular administration into the vastus lateralis muscle and the deltoid muscle. Br J Anaesth 47: 857–862, 1983.

    Google Scholar 

  164. Greenblatt DJ, Shader RI, Abernethy DR: Drug therapy: Current status of benzodiazepines. N Engl J Med 309: 354–358, 1983.

    PubMed  CAS  Google Scholar 

  165. Wilkinson PK: Pharmacokinetics of ethanol: A review. Alcohol Clin Exp Res 4: 6–21, 1980.

    PubMed  CAS  Google Scholar 

  166. Mendels J, Wasserman TW, Michals TJ, Fine EW: Halazepam in the management of acute alcohol withdrawal syndrome. J Clin Psychiatry 46: 172–174, 1985.

    PubMed  CAS  Google Scholar 

  167. Mukherjee PK: A comparison of the efficacy and tolerability of clobazam and chlordiazepoxide in the treatment of acute withdrawal from alcohol in patients with primary alcoholism. J Intern Med Res 11: 205–211, 1983.

    CAS  Google Scholar 

  168. Lister RG: The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 9: 87–94, 1985.

    PubMed  CAS  Google Scholar 

  169. George KA, Dundee JW: Relative amnesic actions of diazepam, flunitrazepam and lorazepam in man. Br J Gin Pharmacol 4: 45–50, 1977.

    CAS  Google Scholar 

  170. Ellinwood EH Jr, Heatherly DG, Nikaido AM, Bjornsson TD, Kilts C: Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 86: 392–399, 1985.

    PubMed  Google Scholar 

  171. Seppala T, Korttila K, Hakkinen S, Linnoila M: Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam. Br J Clin Pharmacol 3: 831–841, 1976.

    PubMed  CAS  Google Scholar 

  172. Baldessarini RJ: Drugs and the treatment of psychiatric disorders, in Gilman AG, Goodman LS, Rall TW, Murad F (eds): The Pharmacological Basis of Therapeutics, 7th. New York, Macmillan, 1985, pp 433–437.

    Google Scholar 

  173. Healy TM, Vickers DM: Laryngeal competence under diazepam sedation. Proc Roy Soc Med 64: 85–86, 1971.

    PubMed  CAS  Google Scholar 

  174. Deutsch JA, Walton NY: Diazepam maintenenance of alcohol preference during alcohol withdrawal. Science 198: 197–199, 1977.

    Google Scholar 

  175. Sampliner R, Iber FL: Diphenylhydantoin contol of alcohol withdrawal seizures. J Am Med Assoc 230: 1430–1432, 1974.

    CAS  Google Scholar 

  176. Walker JE, Homan RW, Vasko RM, Crawford IL, Bell RD, Tasker WG: Lorazepam in status epilepticus. Ann Neurol 6: 207–213, 1979.

    PubMed  CAS  Google Scholar 

  177. Fisher J, Abrams J: Life-threatening ventricular tachyarrythmias in delirium tremens. Arch Intern Med 137: 1238–1241, 1977.

    PubMed  CAS  Google Scholar 

  178. Ballenger JC, Post RM: Kindling as a model for the alcohol withdrawal syndrome. Br J Psychiatry 133: 1–14, 1978.

    PubMed  CAS  Google Scholar 

  179. Racine R: Kindling: The first decade. Neurosurgery 3: 234–252, 1978.

    PubMed  CAS  Google Scholar 

  180. Poldrugo F, Snead OC: Electroencephalographic and behavioral correlates in rats during repeated ethanol withdrawal syndromes. Psychopharmacology 83: 140–146, 1984.

    PubMed  CAS  Google Scholar 

  181. Baker TB, Cannon DS: Potentiation of ethanol withdrawal by prior dependence. Psychopharmacology 60: 105–110, 1979.

    PubMed  CAS  Google Scholar 

  182. Pineal JPJ, Van Oot PH: Generality of the kindling phenomenon: Some clinical implications. J Can Sci Neurologiques Nov: 2: 467–474, 1975.

    Google Scholar 

  183. Stockwell T, Smail P, Hodgson R, Canter S: Alcohol dependence and phobic anxiety states. II. A retrospective study. Br J Psychiatry 144: 58–63, 1984.

    PubMed  CAS  Google Scholar 

  184. George DT, Nutt DJ, Dwyer BA, Linnoila M: Alcoholism and panic disorder: Is the comorbidity more than coincidence? Submitted for publication.

    Google Scholar 

  185. Ewing JA: Detecting alcoholism: The cage questionnaire. J Am Med Assoc 252: 1905–1907, 1984.

    CAS  Google Scholar 

  186. Skolnik P, Schweri MM, William EF, Moncada VY, Paul SM: An in vitro binding assay which differentiates benzodiazepine “agonists” and “antagonists.” Eur J Pharmacol 78: 133–136, 1982.

    Google Scholar 

  187. Eriksson E, Carlsson M, Nilsson C, Soderpalm B: Does alprazolam, in contrast to diazepam, activate alpha2-adrenoceptors involved in the regulation of rat growth hormone secretion? Life Sci 38: 1491–1498, 1986.

    PubMed  CAS  Google Scholar 

  188. Charney DS, Breier A, Jatlow PI, Heninger GR: Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: Interactions with yohimbine. Psychopharmacology 88: 133–140, 1986.

    PubMed  CAS  Google Scholar 

  189. Charney DS, Heninger GR: Noradrenergic function and the mechanism of action of antianxiety treatment. Arch Gen Psychiatry 42: 458–467, 1985.

    PubMed  CAS  Google Scholar 

  190. Chouinard G, Annable L, Fontaine R, Solyom L: Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind, placebo-controlled study. Psychopharmacology 77: 229–233, 1982.

    PubMed  CAS  Google Scholar 

  191. Calogero A, Gold PW, Gallucci W, Loriaux DL, Chrousos GP: Effects of norepinephrine, serotonin, acetylcholine, and GABA in in vitro CRH secretion, in Chrousos GP, Loriaux DL, Gold PW (eds): Mechanisms of Physical and Emotional Stress. New York, Raven Press, in press.

    Google Scholar 

  192. Fabre LF, Melendon DM: A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr Therapeut Res 27: 474–482, 1980.

    Google Scholar 

  193. Feighner JB, Aden GC, Fabre LF, Rickels K, Smith WT: Comparison of alprazolam, imipramine and placebo in the treatment of depression. J Am Med Assoc 249: 3057–3064, 1983.

    CAS  Google Scholar 

  194. Rickels K, Chung HR, Csanalos IB, Hurowitz AH, London J, Wiseman K, Kaplan M, Amsterdam JD: Alprazolam, diazepam, imipramine, placebo in outpatient with major depression. Arch Gen Psychiatry 44: 862–866, 1987.

    PubMed  CAS  Google Scholar 

  195. Wilson A, Vulcano BA: Double-blind trial of alprazolam and chlordiazepoxide in the management of the acute ethanol withdrawal syndrome. Alcohol Clin Exp Res 9: 23–27, 1985.

    PubMed  CAS  Google Scholar 

  196. Cloninger CR, Bohman M, Sigvardsson S: Inheritance of alcohol abuse: Cross-fostering analysis of adopted men. Arch Gen Psychiatry 38: 861–868, 1981.

    PubMed  CAS  Google Scholar 

  197. Bohman M, Cloninger CR, von Knorring A-L, Sigvardsson S: An adoption study of somatoform disorders. III. Cross-fostering analysis and genetic relationship to alcoholism and criminality. Arch Gen Psychiatry 41: 872–878, 1984.

    PubMed  CAS  Google Scholar 

  198. Tarter RE, McBride H, Buonpane H, Scheider DU: Differentiation of alcoholics. Arch Gen Psychiatry 34: 761–768, 1977.

    PubMed  CAS  Google Scholar 

  199. Gittelman-Klein R, Monnuzza S, Shenker R, Bonagura N: Hyperactive children almost grown up. Arch Gen Psychiatry 42: 937–947, 1985.

    Google Scholar 

  200. Thiebot MH, LeBihan C, Soubrie P, Simon P: Benzodiazepines reduce the tolerance to reward delay in rats. Psychopharmacology 86: 147–152, 1985.

    PubMed  CAS  Google Scholar 

  201. Roy A, Virkkunen M, Linnoila M: Reduced central serotonin turnover in a subgroup of alcoholics? Progr Neuropsychopharmacol Biol Psychiatry 11: 173–177, 1987.

    CAS  Google Scholar 

  202. Wise CD, Berger BD, Stein L: Benzodiazepines: Anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 177: 180–183, 1972.

    PubMed  CAS  Google Scholar 

  203. Nutt DJ, Cowen PJ: Diazepam alters brain 5HT function in man: Implications for the acute and chronic effects of benzodiazepines. Psychol Med 17: 601–607, 1987.

    PubMed  CAS  Google Scholar 

  204. Mates J: Psychopharmacology of temper outbursts: A review. J Nerv Ment Dis 174: 464–470, 1986.

    Google Scholar 

  205. Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, McGuire M, Gibbons RD: A double blind, placebo controlled trial of lithiium carbonate therapy for alcoholism. Arch Gen Psychiatry 44: 248–256, 1987.

    PubMed  CAS  Google Scholar 

  206. Schuckit M, Pitts FN, Rech T, King LJ, Winokur G: Alcoholism. I. Two types of alcoholism in women. Arch Gen Psychiatry 20: 301–306, 1969.

    PubMed  CAS  Google Scholar 

  207. Schaefer MR, Sobieraj K, Hollyfield RL: Severity of alcohol dependence and its relationship to additional psychiatric symptoms in male alcoholic in patients. Am J Drug Alc Abuse 13: 435–447, 1987.

    CAS  Google Scholar 

  208. Linnoila M, Mattila MJ, Kitchell BS: Drug interactions with alcohol. Drugs 18: 299–311, 1979.

    PubMed  CAS  Google Scholar 

  209. Rommelspacher H, Strauss S: Down-regulation of cerebral β-adrenoceptors induced by long term administration of anti-depressants is prevented by ethanol, in Lindros Ko, Ylikahri R, Kiianmaa K (eds): Advances in Biomedical Alcohol Research. New York, Pergamon Press, 1987 pp 697–702.

    Google Scholar 

  210. Linnoila M, Martin PR: Benzodiazepines and alcoholism, in Trimble M (ed): Benzodiazepines Divided. London, John Wiley and Sons, 1983, pp 291–308.

    Google Scholar 

  211. Mullaney JA, Trippett CJ: Alcohol dependence and phobias: Clinical description and relevance. Br J Psychiatry 135: 565–573, 1979.

    PubMed  CAS  Google Scholar 

  212. Ko GN, Elsworth JD, Roth RH, Rifkin GB, Leigh H, Redmond E: Panic-induced elevation of plasma MHPG levels in phobic-anxious patients: Effects of Clonidine and imipramine. Arch Gen Psychiatry 40: 425–430, 1983.

    PubMed  CAS  Google Scholar 

  213. Siegel S: Pavlovian conditioning and ethanol tolerance, in Lindros KO, Ylikahri R, Kiianmaa K (eds): Advances in Biomedical Alcohol Research. New York, Pergamon Press, 1987, pp 25–36.

    Google Scholar 

  214. Tabakoff B, Ritzmann RF: The effects of 6-hydroxydopamine on tolerance to and dependence on ethanol. J Pharmacol Exp Ther 203: 319–332, 1977.

    PubMed  CAS  Google Scholar 

  215. Nutt D, Glue P, Molyneux S, Clark E: Alpha-2-adrenoceptor function in alcohol withdrawal: A pilot study on the effects of Clonidine. Alcohol Clin Exp Res 12: 14–18, 1988.

    PubMed  CAS  Google Scholar 

  216. Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety. Arch Gen Psychiatry 37: 51–59, 1980.

    PubMed  CAS  Google Scholar 

  217. Zitrin CM, Klein DF, Woerner MG: Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 37: 63–72, 1980.

    PubMed  CAS  Google Scholar 

  218. Sheehan DV, Coleman JH, Greenblatt DJ, Jones KJ, Levine PH, Orsulak PJ, Peterson M, Schildkraut JJ, Uzogora E, Watkins D: Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 4: 66–75, 1984.

    PubMed  CAS  Google Scholar 

  219. Charney DS, Woods SW, Goodman WK, Krystal JH, Nagy LM, Heninger GM: The efficacy of lorazepam in panic disorders, in New Research Program and Abstracts. American Psychiatric Association, NR 165, 1987, p 110.

    Google Scholar 

  220. Pollack M, Rosenbaum JF, Tesar G, Herman JB, Sachs GS, Cohen LS: Alprazolam versus clonazepam in panic disorders, in New Research Program and Abstracts. American Psychiatric Association, NR 167, 1987, p 111.

    Google Scholar 

  221. Seppala T, Linnoila M: Effects of zimelidine and other antidepressants on skilled performance: A comprehensive review. Acta Psychiatr Scand 68: suppl 308, 135–140, 1983.

    Google Scholar 

  222. Food and Drug Administration: Seizures Associated with Alprazolam: Adverse Event Reporting System. NDA 18-276, Rockville, MD, 1986.

    Google Scholar 

  223. den Boer JA, Westenberg HGM: Panic disorder: Serotonin function and antipanic treatment. Abstract. Second International Symposium on Depression, Anxiety and Aggression, Amsterdam, 1987.

    Google Scholar 

  224. Data on file, Duphar, Weesp, the Netherlands, 1987.

    Google Scholar 

  225. Narenjo CA, Sellers EM, Roach CA, Woodley DV, Sanches-Craig M, Sykora K: Zimelidineinduced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther 35: 374–381, 1984.

    Google Scholar 

  226. v. d. Velden JW, Ottewanger EA: Fluvoxamine in overdoses. Poster. Second International Symposium on Depression, Anxiety and Aggression, Amsterdam, 1987.

    Google Scholar 

  227. Brantigan CO, Brantigan TA, Joseph W: Beta blockers and beta stimulation in stage fright. J Med 72: 88–94, 1982.

    CAS  Google Scholar 

  228. Alstrom JE, Nordlund CL, Persson G, Harding M, Ljungqvist J: For treatment methods in social phobic patients. Acta Psychiatr Scand 70: 97–110, 1984.

    PubMed  CAS  Google Scholar 

  229. Marks IM: Fears, Phobias and Rituals. New York, Oxford University Press, 1987.

    Google Scholar 

  230. Kahn RJ, McNair DM, Covi L, Downing RW, Fisher S, Lipman RS, Rickels K, Smith VK: Effects of psychotropic agents in high anxiety subjects. Psychopharmacol Bull 17: 97–100, 1981.

    Google Scholar 

  231. Johnstone EC, Owens DGC, Frith DC, McPherson K, Dowie C, Riley G, Gold A: Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychol Med 10: 321–328, 1980.

    PubMed  CAS  Google Scholar 

  232. Rickels K, Wiseman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J: Buspirone and diazepam in anxiety. J Clin Psychiatry 43: 81–86, 1982.

    PubMed  CAS  Google Scholar 

  233. Erwin CW, Linnoila M, Hartwell J, Erwin A, Guthrie S: Effects of buspirone and diazepam, alone and in combination with alcohol on skilled performance and evoked potentials. J Clin Psychopharmacol 6: 199–209, 1986.

    PubMed  CAS  Google Scholar 

  234. Cole JO, Orzads MH, Beake B, Bird B, Bar-Tal Y: Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 43: 69–74, 1982.

    PubMed  CAS  Google Scholar 

  235. Griffith JD, Jasinski DR, Casten GP, McKinney GR: Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med 80: 30–35, 1986.

    PubMed  CAS  Google Scholar 

  236. Data on file (10 patients), Bristol-Myers, Evansville, IN, Nov 1987.

    Google Scholar 

  237. Winokur G, Rimmer J, Reich T: Alcoholism IV. Is there more than one type of alcoholism? Br J Psychiatry 118: 525–531, 1971.

    PubMed  CAS  Google Scholar 

  238. Robertson CC, Sellers EM: Alcohol intoxication and the alcohol withdrawal syndrome. Postgrad Med 64: 133–138, 1978.

    PubMed  CAS  Google Scholar 

  239. Linnoila M, Virkkunen M, Roy A: Biochemical aspects of aggression in man, in Bunney WE Jr, Costa E, Potkin SG (eds): Clinical Neuropharmacology. New York, Raven Press, 1986, pp 72–73.

    Google Scholar 

  240. Mendelson WB: Medication in the treatment of sleep disorders, in Melzer H, (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987, pp 1305–1311.

    Google Scholar 

  241. Griffiths RR, Bigelow GE, Liebson I: Double blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther 210: 301–310, 1979.

    PubMed  CAS  Google Scholar 

  242. Griffiths RR, Bigelow GE, Liebson I: Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 40: 865–873, 1983.

    PubMed  CAS  Google Scholar 

  243. Griffiths RR, McLeod DR, Bigelow GE, Liebson IA, Roache JD: Relative abuse liability of diazepam and oxazepam: Behavioral and subjective dose effects. Psychopharmacology 84: 147–154, 1984.

    PubMed  CAS  Google Scholar 

  244. Griffiths RR, McLeod DR, Bigelow GE, Liebson IA, Roache JD, Nowowieski P: Comparison of diazepam and oxazepam: Preference, linking and extent of abuse. J Pharmacol Exp Ther 229: 501–508, 1984.

    PubMed  CAS  Google Scholar 

  245. Roache JD, Griffiths RR: Comparison of triazolam and pentobarbital: Performance impairment, subjective effects and abuse liability. J Pharmacol Exp Ther 234: 120–133, 1985.

    PubMed  CAS  Google Scholar 

  246. Griffiths RR, Lamb RJ, Ator NA, Roache JD, Brady JV: Relative abuse liability of triazolam: Experimental assessment in animals and humans. Neurosci Biobehav Rev 9: 133–151, 1985.

    PubMed  CAS  Google Scholar 

  247. Griffiths RR, Roache JD: Abuse liability of benzodiazepines: A review of human studies evaluating subjective and/or reinforcing effects, in Smith DE, Wesson DR (eds): The Benzodiazepines: Current Standards for Medical Practice, Boston, MTP Press, 1985, pp 209–225.

    Google Scholar 

  248. Bergman U, Griffiths RR: Relative abuse of diazepam and oxepam: Prescription forgeries and theft/loss reports in Sweden. Drug Alc Depend 16: 293–301, 1986.

    CAS  Google Scholar 

  249. Cappell H, Busto U, Kay G, Naranjo CA, Sellers EM, Sanchez-Craig MM: Drug deprivation and reinforcement by diazepam in a dependent population. Psychopharmacology 91: 154–160, 1987.

    PubMed  CAS  Google Scholar 

  250. Winokur A, Ridsels K, Greenblatt DJ, Snyder PJ, Schatz NJ: Withdrawal reaction from long-term low-dosage administration of diazepam. Arch Gen Psychiatry 37: 101–105, 1980.

    PubMed  CAS  Google Scholar 

  251. Nutt DJ: Benzodiazepine dependence in the clinic: Reason for anxiety: Trends Pharmacol Sci 11: 260–457, 1986.

    Google Scholar 

  252. Marks J: The Benzodiazepines: Use, Overuse, Misuse, Abuse. Baltimore, University Park Press, 1978.

    Google Scholar 

  253. Robinson GM, Sellers EM: Diazepam withdrawal seizures. Can Med Assoc J 126: 145–944, 1982.

    Google Scholar 

  254. Gardos G, DiMascio A, Salzman C, Shader RI: Differential actions of chlordiazepoxide and oxzepam on hostility. Arch Gen Psychiatry 18: 757–760, 1968.

    PubMed  CAS  Google Scholar 

  255. Salzman C, Kochansky Ge, Shader RI, Porrino LJ, Harmatz JS, Swelt CP Jr: Chlordiazepoxideinduced hostility in a small group setting. Arch Gen Psychiatry 31: 401–405, 1974.

    PubMed  CAS  Google Scholar 

  256. Kochansky Ge, Salzman C, Shader RI, Harmatz JS, Olgetree AM: The differential effects of chlordiazepoxide and oxazepam on hostility in a small group setting. Am J Psychiatry 132: 861–863, 1987.

    Google Scholar 

  257. Kochansky GE, Salzman C, Shader RI, Harmatz JS, Olgetree AM: Effects of chlordiazepoxide and oxazepam administration on verbal hostility. Arch Gen Psychiatry 34: 1457–1459, 1977.

    PubMed  CAS  Google Scholar 

  258. Ochs HR, Greenblatt DJ, Roberts G-M, Dengler JH: Diazepam interaction with antituberculosis drugs. Clin Pharmacol Ther 29: 671–678, 1981.

    PubMed  CAS  Google Scholar 

  259. Abernethy DR, Greenblatt DJ, Divoll M, Ameer B, Shader RI: Differential effect of Cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): Prevention of acetaminophen toxicity by Cimetidine. J Pharmacol Exp Ther 224: 508–513, 1983.

    PubMed  CAS  Google Scholar 

  260. Greenblatt DJ, Abernethy DR, Koepke HH, Shader RI: Interaction of Cimetidine with oxazepam, lorazepam and flurazepam. J Clin Pharmacol 24: 187–193, 1984.

    PubMed  CAS  Google Scholar 

  261. Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI: Interaction of Cimetidine with the triazolbenzodiazepines alprazolam and triazolam. Psychopharmacology 80: 275–278, 1983.

    PubMed  CAS  Google Scholar 

  262. Abernethy DR, Greenblatt DJ, Eshelman FN, Shader RI: Ranitidine does not impair oxidative or conjugative metabolism: Noninteraction with antipryrine, diazepam, and lorazepam. Clin Pharmacol Ther 35: 188–192, 1984.

    PubMed  CAS  Google Scholar 

  263. Ochs HR, Greenblatt DJ, Eckardt B, Harmatz JS, Shader RI: Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther 33: 471–476, 1983.

    PubMed  CAS  Google Scholar 

  264. Sellers EM, Greenblatt DJ, Giles HG, Naranjo CA, Kaplan H, MacLeod SM: Chlordiazepoxide and oxazepam disposition in cirrhosis. Clin Pharmacol Ther 26: 240–246, 1979.

    PubMed  CAS  Google Scholar 

  265. Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI: Clinical importance of the interaction of diazepam and Cimetidine. N Engl J Med 310: 1639–1643, 1984.

    PubMed  CAS  Google Scholar 

  266. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstom I, Maany I, Neiderhiser D, Nocks JJ, Shaw S: Disulfiram treatment of alcoholism. J Am Med Assoc 256: 1449–1455, 1986.

    CAS  Google Scholar 

  267. Savolainen K, Hervonen H, Lehto V-P, Mattila MJ: Neurotoxic effects of disulfiram on autonomic neurons system in rat. Acta Pharmacol Toxicol 55: 339–344, 1984.

    CAS  Google Scholar 

  268. MacLeod SM, Sellers EM, Giles HG, Billings BJ, Martin PR, Greenblatt DJ, Marshman JA: Interaction of disulfiram with benzodiazepines. Clin Pharmacol Ther 24: 583–589, 1978.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Clinical Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, 20892, USA

    David Nutt, Bryon Adinoff & Markku Linnoila

Authors
  1. David Nutt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bryon Adinoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markku Linnoila
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. New York University School of Medicine, New York, New York, USA

    Marc Galanter

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer Science+Business Media New York

About this chapter

Cite this chapter

Nutt, D., Adinoff, B., Linnoila, M. (1989). Benzodiazepines in the Treatment of Alcoholism. In: Galanter, M. (eds) Recent Developments in Alcoholism. Recent Developments in Alcoholism, vol 7. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1678-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1678-5_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1680-8

  • Online ISBN: 978-1-4899-1678-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation